Quick Info
| Profession | President, CEO of Vertex Pharmaceuticals |
|---|---|
| Nationality | Indian |
| Birthplace | Mumbai, Maharashtra, India |
| Date of Birth | 29/03/1973 |
| Age | 53 years |
Latest News about Reshma Kewalramani
2026
Reshma Kewalramani was named TIME Magazine's Woman of the Year for 2026, recognizing her transformative leadership of Vertex Pharmaceuticals and her significant contributions to global biotechnology. Under her tenure as CEO since April 2020, Vertex's market value has grown from approximately $69 billion to nearly $120 billion, and the company has developed groundbreaking therapies including CRISPR-based gene-editing treatments for sickle cell disease and beta thalassemia.
Do you like Reshma Kewalramani?
You can vote only once.
Bio/Wiki
| Known For | Being the first female CEO of a large US biotech company |
|---|
Physical Stats & More
| Eye Color | Brown |
|---|---|
| Hair Color | Brown |
Educational Qualification(s)
| College/University |
|
|---|---|
| Degrees |
|
Personal Life
| Marital Status | Married |
|---|
Relationships & More
| Children | 2 (twins) |
|---|
Career
| Summary | Reshma Kewalramani began her career as a physician at Massachusetts General Hospital, Brigham and Women's Hospital, Massachusetts Eye and Ear Infirmary, and MIT. She completed training in internal medicine and nephrology, followed by a clinical nephrology fellowship and research in transplantation. She spent over 12 years at Amgen in leadership positions across research and development, eventually becoming Vice President of Global Clinical Development and Vice President of the U.S. Medical Organization. She joined Vertex Pharmaceuticals in 2017 as Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs, assuming the role of President and CEO on April 1, 2020. Under her leadership, Vertex's market value surged from approximately $69 billion to nearly $120 billion within five years, and the company has advanced therapies for cystic fibrosis, sickle cell disease, beta thalassemia, and type 1 diabetes. |
|---|
Social Media
| https://www.facebook.com/reshma.kewalramani/ | |
| https://www.linkedin.com/in/reshma-kewalramani-md-fasn-8328ba21/ |
Some Lesser Known Facts
| 1. Reshma moved to the United States from Mumbai with her family at the age of 11. | |
| 2. She worked as a Resident Physician at Massachusetts General Hospital from 1998 to 2001. | |
| 3. Reshma was a Nephrology Fellow at Partners HealthCare from 2001 to 2002. | |
| 4. Her roles in the field include working as a Nephrologist and Research Fellow at Brigham and Women’s Hospital. | |
| 5. Reshma spent over six years at Amgen, engaging in various positions in Global Clinical Development and Medical Affairs. | |
| 6. She rose to Vice President and Head of the Nephrology and Metabolic Therapeutic Area at Amgen. | |
| 7. In 2025, she achieved FDA approval for Journavx, a groundbreaking pain medication. | |
| 8. An animal enthusiast, Reshma has a pet dog named Snickers. | |
| 9. She actively participates in philanthropy through Vertex Volunteers, supporting global nonprofit work. | |
| 10. She graduated summa cum laude from Boston University in 1998. | |
| 11. Reshma spent over 12 years at Amgen, engaging in various positions in Global Clinical Development and Medical Affairs. | |
| 12. She is a member of the board of directors of the Biomedical Science Careers Program and RIZE Massachusetts. | |
| 13. She serves on the Boston University School of Medicine Dean's Advisory Board, the MGH Board of Trustees, and the Ginkgo Bioworks board of directors. | |
| 14. She is a Fellow of the American Society of Nephrology (FASN) and was on the inaugural board of directors of the Kidney Health Initiative. |